Athens Medical Group | News | Bond Loan Amendment Agreement

Ανακοινώσεις - IR

Bond Loan Amendment Agreement

“Signing of an Amendment Agreement to the Common Bond Loan Issuance Programme dated 12/7/2012, with an outstanding principal amount of €130,962 thousand as of September 30, 2017.”

The “IATRIKO ATHINON” (Athens Medical) Group announces the signing of an amendment agreement to the Common Bond Loan Issuance Programme dated 12/7/2012—established pursuant to the provisions of Codified Law 2190/1920 and Law 3156/2003—executed via a private placement with the banks National Bank of Greece S.A. and EFG Eurobank Ergasias S.A. and ALPHA BANK S.A. (with the latter acting as the facility agent), with an outstanding principal amount of €130,962 thousand as of September 30, 2017.

The key terms of the amended agreement provide for the following:

  • An extension of the maturity date by 3 years, with an option for a further 2-year extension, setting the final principal repayment date to June 20, 2022;
  • An interest period of either six or three months (at the issuer’s discretion), with a reduction in the interest margin to 4% per annum;
  • An amendment to the repayment schedule for the currently outstanding principal, structured into semi-annual installments;
  • Compliance with financial covenants at each reporting date for the Financial Statements (Interim and Annual);
  • The provision of collateral—in addition to that already in place—through:
    • the creation of pledges over movable assets belonging to the Company and its subsidiaries; and
    • the registration of new liens (pre-notations) on real estate assets;

…of the Company and its Subsidiaries.

It is recalled that, in this context, the Extraordinary General Meeting of the Company’s shareholders, held on 20/7/2017—with the sole agenda item being the approval of the provision of collateral in relation to the bond loan agreement dated 12/7/2012—authorized the Board of Directors to negotiate and sign the aforementioned collateral arrangements.

The amended agreement will contribute to the improvement of the Group’s working capital and operating cash flows, while simultaneously ensuring sufficient liquidity to meet its financial and operational requirements.